Online Management of Breast Diseases Patient Education |  Physician Guidelines |  Treatment Index
News |  TransMed |  E-Mail |  Disclaimer

Onc.Protocol:GEMZAR

 

 

ONCOLOGIC PROTOCOL

GEMZAR - STAGE IV

MAJOR INDICATIONS: TREATMENTS FOR STAGE IV BREAST CANCER
IDENTIFICATION: Gemcitabine (Gemzar)
This drug has not been approved by the FDA (Food and Drug Administration) for the treatment of breast cancer, but there is evidence from clinical trials that it is effective against breast cancer.
Doses: 1,000-1,200 mg./M2
Route: Given intravenously (IV)
Duration and timing: Treatments may be given- a) once weekly for up to 7 weeks, followed by 1 week off treatment, with subsequent treatments given weekly for 3 weeks, followed by 1 week off treatment -or- b) once weekly for 3 weeks, followed by 1 week off treatment.
Treatments are generally continued as long as the drug keeps the breast cancer from growing unless there are unacceptable side effects.
Possible Side effects:
  • Hematopoetic: decrease in blood cells, especially white cells (neutropenia) but also red cells (anemia) and or platelets (thrombocytopenia)
  • Gastrointestinal: possible nausea and vomiting (which may be decreased or prevented with medications); diarrhea; constipation; mouth sores; decreased appetite; abnormalities in liver function tests
  • Integmentary: possible hair thinning; skin rash in 25% of people, which may cause itching in about 10% of people
  • Genitourinary: small amounts of protein (proteinurea) and/or blood (hematuria) in the urine, which usually require no medical treatment
  • Fertility: effect on fertility is unknown; this drug should not be taken by women who are pregnant or breast feeding
  • Cardiovascular: edema (swelling or fluid retention) in the feet and ankles or elsewhere; low blood pressure
  • Respiratory: shortness of breath or difficulty breathing
  • Neurological: tingling sensation in hands or feet
  • Other: fatigue and flu like symptoms including fever, chills, and body aches

Back gif

 

1997 - TransMed Network